InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.015 0.365 (56.15%)+
Announcement
Release
24 Feb 2026 9:33AM
Price at Release
$0.650
Full Release
download
Summary
The half-year financial report for OncoSil Medical Ltd, covering the period ending 31 December 2025, outlines significant financial movements, including a 70.5% increase in revenues from ordinary activities to $782,895 and a 329.3% increase in other income and interest revenue to $2,443,913. Despite these increases, the company reported a net loss of $4,525,069, marking a 32.5% reduction in loss compared to the previous year. The financial position indicates total assets of $7,131,101 with net tangible assets per ordinary security decreasing from 74.36 cents to 20.42 cents. This report also highlights significant equity transactions, including share issues and options granted, which contributed to a positive cash flow from financing activities of $4,717,946. The report includes an audit review that highlighted a material uncertainty related to going concern.
Key Points
  • Revenues from ordinary activities increased by 70.5% to $782,895.
  • Other income and interest revenue increased by 329.3% to $2,443,913.
  • Net loss reduced by 32.5% to $4,525,069.
  • No dividends were declared during the period.
  • Net tangible assets per ordinary security decreased from 74.36 cents to 20.42 cents.
  • Significant share issues and options granted were detailed.
  • Positive cash flow from financing activities totaled $4,717,946.
  • Material uncertainty related to going concern was noted in the audit review.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.